GC Pharma is busy building a lineup of ARB-based hypertension drugs called Candesartan. If Atacand, which is Candesartan's original product, has been sold for a long time, it can be seen as a measure to actively utilize its distribution network. It is currently pushing for development of other complexes in addition to single and two complexes.

The MFDS approved a Phase I clinical trial plan for the test drug "GC2121" submitted by GC Pharma on the 8th.

This clinical trial will be conducted to evaluate safety, pharmacokinetic and drug interactions when administered Candesartan 32 mg/Dapagliflozin 10 mg to healthy adult volunteers. It is interpreted as an early clinical trial to verify the c